A long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice

• Main Authors: Kripa Shankar (Author), Nathan P. Metzger (Author), Connor Lawrence (Author), Deepali Gupta (Author), Sherri Osborne-Lawrence (Author), Salil Varshney (Author), Omprakash Singh (Author), Corine P. Richard (Author), Alexander N. Zaykov (Author), Rebecca Rolfts (Author), Barent N. DuBois (Author), Diego Perez-Tilve (Author), Bharath K. Mani (Author), Suntrea T.G. Hammer (Author), Jeffrey M. Zigman (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The number of individuals affected by metabolic dysfunction associated fatty liver disease [1] is on the rise, yet hormonal contributors to the condition remain incompletely described and only a single FDA-approved treatment is available. Some studies suggest that the hormones ghrelin and...